For the asthma indication, Spiriva® Respimat® is licensed for use as an add-on maintenance bronchodilator treatment in adults who are currently treated with the maintenance combination of inhaled corticosteroids (≥800 µg budesonide/day or equivalent) and long-acting β2 agonists and who experienced one or more severe exacerbations in the previous year.
Previous AWMSG advice, issued in 2016 (0516), did not recommend its use for this indication, as the company submission did not present sufficient evidence to demonstrate that it is cost-effective.